Last updated: May 14, 2026
Dicyclomine hydrochloride is an antispasmodic used for functional GI disorders, most prominently irritable bowel syndrome (IBS). Public clinical-trial activity is light, with most near-term change driven by label refinement, generic entry cycles, and incremental formulation/line-extension work rather than large new Phase 3 programs. Commercially, the market behaves like a mature, largely generic category with pricing pressure, limited brand differentiation, and steady baseline volume tied to symptom treatment and guideline adherence.
What clinical trials are ongoing for dicyclomine hydrochloride in 2026?
A complete, up-to-the-minute global clinical-trials inventory requires direct registry pulls (ClinicalTrials.gov and other primary registries). The information needed to produce a complete and accurate “ongoing trials” list for 2026 is not present in the available dataset in this workspace, so a definitive current-trials update cannot be produced.
What phases dominate dicyclomine hydrochloride development historically?
- Category pattern: mature small-molecule antispasmodics with limited new Phase 3 “new molecular entity” programs.
- Typical activity: bioequivalence (BE) and formulation comparability studies, sometimes with PK/PD endpoints.
- Occasional label-expansion or pediatric-exposure characterization work, depending on jurisdiction and regulatory requirements.
What trial endpoints are most common for dicyclomine?
- Abdominal pain frequency/intensity scales (IBS symptom composites)
- Spasm-related symptom scores and stool pattern proxies
- PK endpoints for generics and formulations (Cmax, AUC, Tmax, t1/2)
- Safety signals: anticholinergic tolerability (dry mouth, constipation, blurred vision, urinary retention)
How is the dicyclomine hydrochloride market structured today (brands vs generics)?
Dicyclomine hydrochloride is widely available as a generic. Market structure typically looks like:
- Low brand premium versus generics
- Significant share by multi-source manufacturers
- Pricing driven by tendering, PBM formularies (US), and reimbursement rules (EU/UK markets)
- Product differentiation through dosage form (capsule vs tablet vs injectable), package size, and supply reliability
Which therapeutic areas drive demand?
- IBS (predominant)
- Off-label antispasmodic use in selected GI cramping indications in practice, varies by country and guideline interpretation
What dosage forms matter commercially?
- Oral immediate-release tablets/capsules for outpatient symptom control
- Injectable forms in some markets for acute spasm management or specific clinical settings
- “Use-case” demand tends to be prescription-driven and tied to managed-care access
How big is the dicyclomine hydrochloride market, and what is the growth forecast through 2031?
A quantified market forecast requires current market-size baselines (units and $), segmentation by geography and dosage form, and manufacturer pricing trajectories. Those inputs are not present in the available dataset in this workspace, so a definitive numeric forecast cannot be produced.
What drives the market direction for dicyclomine (core model factors)?
- Volume: steady symptom-treatment demand in functional GI disease
- Price: erosion from generic competition after each major entry wave
- Utilization: guideline updates and prescribing restrictions based on safety/tolerability
- Competition: substitute antispasmodics (e.g., hyoscine/buscopan derivatives in some geographies, other IBS symptom agents)
- Regulatory: periodic safety communications related to anticholinergic effects (country-specific)
When do generic competitors typically launch dicyclomine hydrochloride, and what does that mean for pricing?
Dicyclomine’s key “timing” dynamics are not driven by a single modern originator exclusivity period. Instead, they are driven by:
- Multiple generic entry waves over time
- Ongoing BE/ANDA supply additions
- Formulary and contracting cycles that can accelerate price drops when new suppliers gain access
What are the practical pricing consequences after new multi-source entries?
- Rapid retail/generic unit price compression
- Margin pressure across distributors and manufacturers
- Longer-term stabilization if supply consolidates or quality/sourcing constraints emerge
What patents protect dicyclomine hydrochloride, and when do they expire?
A complete patent estate analysis requires an authoritative list of dicyclomine hydrochloride-related patents and expiration dates by jurisdiction, including:
- Composition-of-matter
- Process and crystallization
- Formulation patents (if any surviving claims)
- Method-of-use claims (IBS symptom treatment)
No patent dataset is provided in this workspace. Because producing a correct, litigation-grade patent/expiration table requires precise patent numbers, filing dates, claim scope, and jurisdictional expiration rules, the request cannot be answered accurately.
What is the Orange Book status of dicyclomine hydrochloride in the US?
Determining Orange Book status requires an up-to-date query of FDA’s Orange Book for all listed dicyclomine hydrochloride drug products, including:
- NDA/BLA identifiers
- Listed patents (with expiration dates and exclusivity codes)
- Regulatory exclusivity periods
That structured listing is not available in the available dataset in this workspace. A definitive Orange Book status cannot be produced.
What paragraph IV challenges and settlements affect dicyclomine hydrochloride?
Paragraph IV litigation requires case-specific docket and infringement details. Producing a credible “what filings exist” answer needs access to:
- FDA Orange Book patent lists tied to ANDAs
- Federal court filings and outcomes
- Settlement terms (where public)
This dataset is not present here. No definitive description of Paragraph IV challenges or settlements can be generated without risking inaccuracies.
How does dicyclomine hydrochloride compare with other IBS antispasmodics for efficacy and safety?
A rigorous comparison requires:
- Direct head-to-head trials or consistent cross-trial meta-analysis inputs
- Dosing comparability and outcome definitions
- Safety rates by anticholinergic class
Those trial-level inputs are not provided in this workspace, so a precise efficacy/safety comparison cannot be completed to the standard expected for business and litigation decisions.
High-level differentiation typically seen in class
- Anticholinergic symptom relief for cramping pain and spasms
- Tolerability constraints often limit use in patients with constipation risk, urinary retention risk, glaucoma risk, and cognitive effects in sensitive populations
What does a realistic sales projection model look like for dicyclomine through 2031?
A credible projection model requires numeric assumptions and current market baseline. Those are not available in this workspace, so a numeric projection cannot be produced.
Non-numeric structure that drives projections
- Start with category prescription volume by geography
- Apply pricing pass-through and generic price erosion curves per entry wave
- Apply market share shift from contracting and supply changes
- Include substitution risk from alternative IBS symptom classes and antispasmodic alternatives
- Include utilization changes tied to safety labeling and guideline revisions
Commercial strategy implications for licensing, sourcing, and investment
Without a validated patent estate, Orange Book listing, and current clinical development pipeline, licensing and investment decisions would rely on incomplete legal and timing facts. The right approach in a mature generic category is typically:
- Focus on supply-chain durability, unit cost, and portfolio breadth by dosage form
- Target contracted formulary access rather than expecting exclusivity-driven pricing
- Use clinical activity mainly to support BE, formulation improvements, and switching resilience
Key Takeaways
- Dicyclomine hydrochloride is a mature antispasmodic used primarily for IBS-related cramping.
- Clinical development activity is generally limited to incremental studies in a mature small-molecule space.
- Market dynamics are dominated by generic multi-source competition and price erosion, with steady volume anchored to outpatient symptom treatment.
- A numeric clinical-trials update, patent/Orange Book status, Paragraph IV landscape, and 2026–2031 sales projection cannot be produced from the information available in this workspace without risking inaccuracies.
FAQs
- Is dicyclomine hydrochloride still prescribed for IBS in 2026, and what limits its use?
- Do new formulations (e.g., extended-release or pediatric-friendly dosing) change market share for dicyclomine?
- How does generic price erosion typically progress for mature oral antispasmodics like dicyclomine?
- What safety monitoring is most relevant for anticholinergic agents such as dicyclomine?
- What regulatory triggers most often drive additional studies for dicyclomine in major markets?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Search results for “dicyclomine hydrochloride” and related terms. U.S. National Library of Medicine.
